Nintedanib Esylate is an orally administered triple angiokinase inhibitor primarily used for the treatment of diseases related to angiogenesis and fibrosis.
I. Basic Information
English Name: Nintedanib Esylate
CAS Number: 656247-18-6
II. Pharmacological Effects
Nintedanib Esylate exerts its pharmacological effects by inhibiting multiple receptor tyrosine kinases, which play crucial roles in angiogenesis and tumor growth. Specifically, it can simultaneously block the activities of vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR α and β), and fibroblast growth factor receptors (FGFR 1-3). This multi-target inhibition makes Nintedanib Esylate effective in the treatment of various diseases.
III. Clinical Applications
Idiopathic Pulmonary Fibrosis (IPF):
Nintedanib Esylate is approved for the treatment of idiopathic pulmonary fibrosis, a chronic, progressive lung disease characterized by increased fibrotic connective tissue in the lung tissue and scarring, leading to worsened lung function and dyspnea.
By inhibiting the activities of multiple receptor tyrosine kinases, Nintedanib Esylate can slow down the progression of idiopathic pulmonary fibrosis.
Non-Small Cell Lung Cancer (NSCLC):
Nintedanib Esylate is also used for the treatment of non-small cell lung cancer, particularly as a first-line treatment for advanced or metastatic NSCLC.
It is usually combined with chemotherapy drugs to target and inhibit tumor angiogenesis and growth pathways, thereby inhibiting tumor growth and spread.
